文献速递肿瘤 PET/CT

肿瘤栖息地与代谢热点位移分析预测不可切除局部晚期NSCLC治疗反应与进展

Integrated tumor habitat and metabolic hot spot displacement analysis on [¹⁸F]FDG PET/CT for predicting treatment response and progression in unresectable locally advanced NSCLC: a two-center competing risk study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-06-17

该回顾性双中心研究纳入403例不可切除局部晚期非小细胞肺癌(LA-NSCLC)患者,基于基线[¹⁸F]FDG PET/CT提取肿瘤栖息地与代谢热点位移(MHSD)特征。栖息地模型在训练、验证和留出测试队列的AUC分别为0.843、0.822和0.847,优于全肿瘤影像组学和临床PET/CT模型。栖息地评分、EPS-SUVmax及胃泌素释放肽前体是影像学确认进展的独立预测因素。

要点

  • 栖息地模型预测治疗反应的AUC在三个队列中为0.843、0.822和0.847。
  • 栖息地评分每增加0.1单位,进展风险sHR为1.49(95%CI 1.31-1.70,P<0.001)。
  • EPS-SUVmax和胃泌素释放肽前体也是进展的独立预测因素。

核心结论

  • 基于[¹⁸F]FDG PET/CT的肿瘤栖息地与MHSD联合评估可能改善不可切除LA-NSCLC的治疗反应预测和进展风险分层。

研究设计与样本

  • 回顾性双中心研究纳入403例不可切除LA-NSCLC患者,随机分为训练组241例、验证组81例和留出测试组81例。
  • 使用Otsu阈值算法勾画四种代谢-密度栖息地并生成栖息地评分,量化MHSD和边缘邻近评分(EPS)。
  • 采用Fine-Gray竞争风险回归评估影像学确认进展的独立预测因素。

主要发现

  • 栖息地模型在训练、验证和留出测试队列的AUC分别为0.843(95%CI 0.789-0.895)、0.822(95%CI 0.725-0.904)和0.847(95%CI 0.744-0.935)。
  • 栖息地模型优于影像组学模型和临床PET/CT模型。
  • 多变量Fine-Gray分析中,胃泌素释放肽前体升高(sHR 1.86,95%CI 1.23-2.81,P=0.004)、栖息地评分每增加0.1单位(sHR 1.49,95%CI 1.31-1.70,P<0.001)和EPS-SUVmax(sHR 1.80,95%CI 1.13-2.88,P=0.014)是影像学确认进展的独立预测因素。

关键数值与推荐

  • 栖息地模型预测治疗反应的AUC在训练队列为0.843(95%CI 0.789-0.895),验证队列为0.822(95%CI 0.725-0.904),留出测试队列为0.847(95%CI 0.744-0.935)。
  • 进展风险的独立预测因素包括胃泌素释放肽前体升高(sHR 1.86,95%CI 1.23-2.81,P=0.004)、栖息地评分每增加0.1单位(sHR 1.49,95%CI 1.31-1.70,P<0.001)和EPS-SUVmax(sHR 1.80,95%CI 1.13-2.88,P=0.014)。

临床怎么用

  • 对于不可切除LA-NSCLC患者,基线[¹⁸F]FDG PET/CT的栖息地评分和MHSD特征可辅助预测治疗反应和进展风险。
  • 栖息地模型提供的预后信息超越常规影像组学和临床PET/CT指标,可整合至风险分层流程。

局限性

  • 回顾性设计可能引入选择偏倚。
  • 影像生物标志物在不同治疗方案中的具体预测效用仍需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the predictive value of [¹⁸F]FDG PET/CT derived tumor habitats and metabolic hot spot displacement (MHSD) for treatment response and disease progression in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). METHODS: This retrospective two-center study included 403 patients with unresectable LA-NSCLC who underwent baseline [¹⁸F]FDG PET/CT before antitumor therapy. The cohort was randomly divided into training (n = 241, 60%), validation (n = 81, 20%), and held-out testing (n = 81, 20%) cohorts. Four metabolic-density habitats were delineated using the Otsu thresholding algorithm to generate a habitat score. MHSD and the edge proximity score (EPS) were quantified to describe the spatial localization of metabolic dominance. The habitat model was compared with whole-tumor radiomics and clinical PET/CT models by the area under the receiver operating characteristic curve (AUC). Independent predictors of radiographically confirmed progression were evaluated using Fine-Gray competing risk regression. RESULTS: The habitat model achieved AUCs of 0.843 (95% confidence interval [CI], 0.789-0.895), 0.822 (95% CI, 0.725-0.904), and 0.847 (95% CI, 0.744-0.935) in the training, validation, and held-out testing cohorts, respectively, and outperformed the radiomics and clinical PET/CT models. In multivariable Fine-Gray analysis, elevated pro-gastrin-releasing peptide (subdistribution hazard ratio [sHR], 1.86; 95% CI, 1.23-2.81; P = 0.004), higher Habitat Score per 0.1-unit increase (sHR, 1.49; 95% CI, 1.31-1.70; P < 0.001), and EPS-SUVmax (sHR, 1.80; 95% CI, 1.13-2.88; P = 0.014) were independent predictors of radiographically confirmed progression. CONCLUSION: Integrated assessment of tumor habitats and MHSD on [¹⁸F]FDG PET/CT may improve treatment-response prediction and progression-risk stratification in unresectable LA-NSCLC. These imaging biomarkers provide prognostic information beyond conventional radiomics and clinical PET/CT indices, though their specific predictive utility across distinct therapeutic regimens warrants prospective validation.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ji Y, Qi H, Zhou M, et al. Integrated tumor habitat and metabolic hot spot displacement analysis on [¹⁸F]FDG PET/CT for predicting treatment response and progression in unresectable locally advanced NSCLC: a two-center competing risk study. Eur J Nucl Med Mol Imaging. 2026. PMID: 42307755. doi:10.1007/s00259-026-08008-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。